Taysha Gene Therapies to Participate in Upcoming May Investor Healthcare Conferences
Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in two virtual events: the 2021 RBC Capital Markets Global Healthcare Conference on May 19 at 3:05 PM ET and the Oppenheimer Rare & Orphan Disease Summit on May 21 at 4:35 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference and a virtual presentation at the Oppenheimer Rare & Orphan Disease Summit.
Conference Details: |
||
Event: |
2021 RBC Capital Markets Global Healthcare Conference |
|
Date: |
Wednesday, May 19, 2021 |
|
Time: |
3:05 pm ET |
|
Format: |
Fireside chat |
|
Participants: |
RA Session II, President, Founder and CEO |
|
|
Dr. Suyash Prasad, Chief Medical Officer and Head of Research and Development |
|
|
Kamran Alam, Chief Financial Officer |
|
|
|
|
Event: |
Oppenheimer Rare & Orphan Disease Summit |
|
Date: |
Friday, May 21, 2021 |
|
Time: |
4:35 pm ET |
|
Format: |
Presentation |
|
Participants: |
RA Session II, President, Founder and CEO |
|
|
Dr. Suyash Prasad, Chief Medical Officer and Head of Research and Development |
|
|
Kamran Alam, Chief Financial Officer |
|
Webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512006057/en/